US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AdvisorShares Psychedelics ETF

25.18

+0.40681.64%

Volume:12.40K

Turnover:311.62K

Market Cap:58.41M

PE:- -

High:25.24

Open:24.74

Low:24.74

Close:24.77

52wk High:27.02

52wk Low:15.63

Shares:2.32M

Float Shares:2.32M

Volume Ratio:1.60

T/O Rate:0.53%

Dividend:1.70

Dividend Rate:6.77%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Compass Pathways - Continue to Expect Commercial Launch in H1 2027

THOMSON REUTERS

Compass Pathways - Comp360 Safety Profile in Part C Consistent with Prior Parts; no New Safety Findings

THOMSON REUTERS

Compass Pathways - 25 Mg Arm Shows Average 13-Point Madrs Reduction at Week 52 with Durability to 1 Year

THOMSON REUTERS

Aureka launches placement and share purchase plan to fund mine expansion and exploration

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

BioAge Labs doses first patient in QUELL-DME study

Relmada Therapeutics Says CMO-Urology Raj S. Pruthi Departs

Bristol Myers’ arlocabtagene autoleucel shows positive results in Phase 2 trial

NRx Pharma to Present at Moody Capital Solutions Disruptive Growth & Life Sciences Conference

FBR raises A$4m to accelerate DST-powered robotics rollout

Mizuho survey shows no consensus into Alkermes ADHD data

Right Resources shareholders back director placements and capital raising

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34

Compass Pathways Grants Inducement Equity Awards Covering 414,100 Shares to New Hires

CARDIO-TTRansform Update: What Eplontersen’s Phase 3 Completion Means for AstraZeneca Investors

WasteCo launches capital raising to fund Ashburton contract and turnaround plan

Talisman Mining Raises A$4 Million to Fast-Track Gold Exploration and Growth

Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874

Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/PSIL/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PSIL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","market":"US","secType":"STK","nameCN":"AdvisorShares Psychedelics ETF","latestPrice":25.175,"timestamp":1789396409290,"preClose":24.7682,"halted":0,"volume":12402,"delay":0,"changeRate":0.0164242859796029,"floatShares":2319976,"shares":2319976,"eps":0,"marketStatus":"Trading","change":0.4068,"latestTime":"09-14 10:41:07 EDT","open":24.7417,"high":25.24,"low":24.7417,"amount":311618.865402,"amplitude":0.020119,"askPrice":25.47,"askSize":100,"bidPrice":25.1,"bidSize":180,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":24.7682,"sharesOutstanding":1184976,"nav":24.85,"aum":57650992.8,"dividendRate":0.067718,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":25.15,"preClose":24.7682,"latestTime":"08:50 EDT","volume":963,"amount":24219.650304,"timestamp":1789390215802,"change":0.3818,"changeRate":0.015415,"amplitude":0.002019},"postHourTrading":{"tag":"盘后","latestPrice":24.82,"preClose":24.7682,"latestTime":"19:30 EDT","volume":41,"amount":1012.1888,"timestamp":1789169404986,"change":0.0518,"changeRate":0.002091,"amplitude":0},"volumeRatio":1.598642,"impliedVol":0.3237,"impliedVolPercentile":0.4382},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PSIL\",,,,,undefined,":{"symbol":"PSIL","floatShares":2319976,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.598642,"shares":2319976,"dividePrice":1.7048,"high":25.24,"amplitude":0.020119,"preClose":24.7682,"low":24.7417,"week52Low":15.6348,"pbRate":"--","week52High":27.0175,"institutionHeld":0,"latestPrice":25.175,"committee":0.285714,"eps":0,"divideRate":0.067718,"volume":12402,"delay":0,"ttmEps":0,"open":24.7417,"prevYearClose":17.17,"prevWeekClose":24.7682,"prevMonthClose":24.62,"prevQuarterClose":24.05,"fiveDayClose":24.86,"twentyDayClose":25.2736,"sixtyDayClose":19.8284},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PSIL\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"PSIL","amount":1.68387,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-29","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-29"},{"date":"2025-09-22","symbol":"PSIL","amount":0.02007,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-29"},{"date":"2025-06-23","symbol":"PSIL","amount":0.01191,"announcedDate":"2025-06-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"},{"date":"2025-03-21","symbol":"PSIL","amount":0.16343,"announcedDate":"2025-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-21","defaultRemindTime":1742563800000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-21","currency":"USD","dateTimestamp":1742529600000,"payDate":"2025-03-28"},{"date":"2024-12-23","symbol":"PSIL","amount":0.05477,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"AdvisorShares Psychedelics ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-30","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PSIL\",market:\"US\",,,undefined,":[{"executeDate":"2022-09-26","recordDate":"2022-09-27","paymentDate":"2022-09-30","value":0.05421,"currency":"USD"},{"executeDate":"2023-09-25","recordDate":"2023-09-26","paymentDate":"2023-09-29","value":0.00336,"currency":"USD"},{"executeDate":"2024-09-23","recordDate":"2024-09-23","paymentDate":"2024-09-30","value":0.1087,"currency":"USD"},{"executeDate":"2024-12-23","recordDate":"2024-12-23","paymentDate":"2024-12-30","value":0.05477,"currency":"USD"},{"executeDate":"2025-03-21","recordDate":"2025-03-21","paymentDate":"2025-03-28","value":0.16343,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PSIL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PSIL\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666584015","title":"Compass Pathways - Continue to Expect Commercial Launch in H1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584015","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584015?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA4GLXR1:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666458406","title":"Compass Pathways - Comp360 Safety Profile in Part C Consistent with Prior Parts; no New Safety Findings","url":"https://stock-news.laohu8.com/highlight/detail?id=2666458406","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666458406?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA4GLXR1:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666054584","title":"Compass Pathways - 25 Mg Arm Shows Average 13-Point Madrs Reduction at Week 52 with Durability to 1 Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2666054584","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666054584?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:30","pubTimestamp":1788949800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nTUA4GLXR1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666303585","title":"Aureka launches placement and share purchase plan to fund mine expansion and exploration","url":"https://stock-news.laohu8.com/highlight/detail?id=2666303585","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666303585?lang=en_us&edition=fundamental","pubTime":"2026-09-09 07:53","pubTimestamp":1788911605,"startTime":"0","endTime":"0","summary":"Aureka Limited ( ($AU:AKA) ) just unveiled an update. Aureka Limited has launched a capital raising initiative comprising a $5.65 million share pla...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aureka-launches-placement-and-share-purchase-plan-to-fund-mine-expansion-and-exploration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aureka-launches-placement-and-share-purchase-plan-to-fund-mine-expansion-and-exploration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4122","AKA","PSIL","BK4094"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNTL","IBBQ","BIB","RSPH","JHMH","GNMX","PBPH","IEIH","IBRN","NVIB","APXH","AZNH","LLYX","HYLG","IBB","HRTS","CURE","SURI","CNCR","PJP","BBP","JDOC","PTH","MDTX","IBBJ","FTXH","WDNA","PBE","GSKH","SBIO","FBT","MEDI","BBH","GNOM","LFSC","MRNY","GDOC","FHLC","CANC","PSCH","TBXU","GPCR","SYNB","FXH","IDNA","BME","MEDX","XPH","PINK","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","SBIO","GSKH","FHLC","IBBQ","BME","MDTX","RSPH","LLYX","CNCR","CURE","PBE","PJP","JDOC","IBBJ","BIB","CANC","LFSC","SYNB","FTXH","JHMH","PTH","IBRN","BBH","GPCR","TBXU","WDNA","PBPH","NVIB","HYLG","PSCH","SURI","PSIL","IBB","MEDI","BBP","FBT","PINK","FXH","MEDX","MNTL","HRTS","XPH","AZNH","GNMX","APXH","LENZ","GDOC","GNOM","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665037847","title":"BioAge Labs doses first patient in QUELL-DME study","url":"https://stock-news.laohu8.com/highlight/detail?id=2665037847","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665037847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:35","pubTimestamp":1788870924,"startTime":"0","endTime":"0","summary":"BioAge Labs (BIOA) announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bioage-labs-doses-first-patient-in-quell-dme-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bioage-labs-doses-first-patient-in-quell-dme-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BIOA","BK4007","BBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665676320","title":"Relmada Therapeutics Says CMO-Urology Raj S. Pruthi Departs","url":"https://stock-news.laohu8.com/highlight/detail?id=2665676320","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665676320?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:05","pubTimestamp":1788869106,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics says CMO-Urology Raj S. Pruthi departsRelmada Therapeutics’ Chief Medical Officer – Urology, Raj S. Pruthi, left the company on Sept. 3, 2026.Disclaimer:This news brief was create","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL6M2JyT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4007","RLMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665327821","title":"Bristol Myers’ arlocabtagene autoleucel shows positive results in Phase 2 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2665327821","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665327821?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:11","pubTimestamp":1788865885,"startTime":"0","endTime":"0","summary":"Bristol Myers (BMY) announced positive Phase 2 results from the registrational QUINTESSENTIAL trial of arlocabtagene autoleucel in adult patients w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bristol-myers-arlocabtagene-autoleucel-shows-positive-results-in-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bristol-myers-arlocabtagene-autoleucel-shows-positive-results-in-phase-2-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","LU1883839398.USD","IE0009355771.USD","LU1670710661.SGD","LU0267386448.USD","BMY","LU0321505868.SGD","LU1291159041.SGD","LU1236620834.HKD","BK4126","LU1074936037.SGD","LU1430594728.SGD","LU1670711123.USD","LU1983299246.USD","LU0985481810.HKD","BBC","LU0456855351.SGD","LU2360032135.SGD","LU0868494617.USD","LU0432979614.USD","LU2596442595.SGD","LU1261432733.SGD","LU1032466523.USD","LU0114720955.EUR","BK4559","BK4588","LU2242652126.USD","LU0882574055.USD","LU1236620750.USD","LU2125154935.USD","IHE","LU1989771016.USD","FTXH","IE00BSNM7G36.USD","LU1093756168.USD","LU1868837300.USD","IE00BJJMRZ35.SGD","LU1868836914.USD","PSIL","LU0237698245.USD","LU0061475181.USD","BK4534","BK4585","LU0225284248.USD","LU1093756325.SGD","LU2133065610.SGD","LU1718418525.SGD","MYE","LU1670710588.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322488","title":"NRx Pharma to Present at Moody Capital Solutions Disruptive Growth & Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322488","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322488?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:06","pubTimestamp":1788865578,"startTime":"0","endTime":"0","summary":"NRx Pharma to present at Moody Capital Solutions Disruptive Growth & Life Sciences ConferenceNRx Pharmaceuticals management will present at investor conferences in New York on Sept. 9, Sept. 11, Sept.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL1TRKCH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","CFSU","SG9999014005.SGD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2210150020.SGD","NRXP","BK4112","LU0314104364.USD","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","BCDF","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR","SG9999014013.SGD","PSIL","SG9999014039.USD","IE00BN0W2V16.EUR","LU2095319765.USD","BK4007","IE00BGHQF748.EUR","IE00BQXX3F31.USD","BK4588","NDAQ","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665138360","title":"FBR raises A$4m to accelerate DST-powered robotics rollout","url":"https://stock-news.laohu8.com/highlight/detail?id=2665138360","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665138360?lang=en_us&edition=fundamental","pubTime":"2026-09-07 07:51","pubTimestamp":1788738718,"startTime":"0","endTime":"0","summary":"The latest announcement is out from FBR Limited ( ($AU:FBR) ). FBR Limited has launched a A$4 million capital raising comprising a A$1.5 million sh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fbr-raises-a4m-to-accelerate-dst-powered-robotics-rollout?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fbr-raises-a4m-to-accelerate-dst-powered-robotics-rollout?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DYNI","PSIL","PBOT","DARP","KOMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665735956","title":"Mizuho survey shows no consensus into Alkermes ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2665735956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665735956?lang=en_us&edition=fundamental","pubTime":"2026-09-05 03:35","pubTimestamp":1788550508,"startTime":"0","endTime":"0","summary":"Mizuho conducted a survey of 13 investors ahead of Alkermes (ALKS)’ Phase 1b trial of ALKS-7290 in adult attention-deficit/hyperactivity disorder, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBRN","FBT","BK4139","ALKS","MEDX","PSCH","PSIL","ADHD","ABVC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664386764","title":"Right Resources shareholders back director placements and capital raising","url":"https://stock-news.laohu8.com/highlight/detail?id=2664386764","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664386764?lang=en_us&edition=fundamental","pubTime":"2026-09-04 12:17","pubTimestamp":1788495451,"startTime":"0","endTime":"0","summary":"Right Resources Limited ( ($AU:RRE) ) has shared an announcement. Right Resources Limited has reported that all resolutions put to shareholders at ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/right-resources-shareholders-back-director-placements-and-capital-raising?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/right-resources-shareholders-back-director-placements-and-capital-raising?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664802637","title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2664802637","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664802637?lang=en_us&edition=fundamental","pubTime":"2026-09-04 06:33","pubTimestamp":1788474793,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin disposes of 2,034 common shares worth $97,651.34Alkermes EVP and chief legal officer David Joseph Gaffin sold 2,034 ordinary shares on Sep. 3, 2026 at USD 48.01.D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL5DSLJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","IBRN","BK4139","ALKS","FBT","PSCH","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664014408","title":"Compass Pathways Grants Inducement Equity Awards Covering 414,100 Shares to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2664014408","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664014408?lang=en_us&edition=fundamental","pubTime":"2026-09-04 04:30","pubTimestamp":1788467422,"startTime":"0","endTime":"0","summary":"Compass Pathways grants inducement equity awards covering 414,100 shares to new hiresCompass Pathways granted inducement equity awards on Sept. 1, 2026 to 31 newly hired non-executive employees.Option","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL1B01xs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664338805","title":"CARDIO-TTRansform Update: What Eplontersen’s Phase 3 Completion Means for AstraZeneca Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2664338805","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664338805?lang=en_us&edition=fundamental","pubTime":"2026-09-04 00:30","pubTimestamp":1788453041,"startTime":"0","endTime":"0","summary":"AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The CARDIO-TTRansform study is a Phase 3 trial that tests eplontersen in p...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cardio-ttransform-update-what-eplontersens-phase-3-completion-means-for-astrazeneca-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cardio-ttransform-update-what-eplontersens-phase-3-completion-means-for-astrazeneca-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4211","BBC","ISBC","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841116","title":"WasteCo launches capital raising to fund Ashburton contract and turnaround plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841116","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841116?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:47","pubTimestamp":1788382036,"startTime":"0","endTime":"0","summary":"WasteCo Group Limited ( ($NZ:WCO) ) has shared an update. WasteCo Group Limited has launched a capital raising comprising a placement and share pur...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/wasteco-launches-capital-raising-to-fund-ashburton-contract-and-turnaround-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/wasteco-launches-capital-raising-to-fund-ashburton-contract-and-turnaround-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664862521","title":"Talisman Mining Raises A$4 Million to Fast-Track Gold Exploration and Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2664862521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664862521?lang=en_us&edition=fundamental","pubTime":"2026-09-02 07:44","pubTimestamp":1788306290,"startTime":"0","endTime":"0","summary":"Talisman Mining Limited ( ($AU:TLM) ) has issued an update. Talisman Mining Limited has launched its first capital raising in over a decade, securi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/talisman-mining-raises-a4-million-to-fast-track-gold-exploration-and-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/talisman-mining-raises-a4-million-to-fast-track-gold-exploration-and-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664864142","title":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874","url":"https://stock-news.laohu8.com/highlight/detail?id=2664864142","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664864142?lang=en_us&edition=fundamental","pubTime":"2026-09-02 07:09","pubTimestamp":1788304180,"startTime":"0","endTime":"0","summary":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson disposes of 9,000 shares for $422,874Craig C. Hopkinson, EVP R&D, Chief Medical Officer, sold 9,000 ordinary shares on Sep. 1 at USD 46.99.He","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDLgbNz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP R&D, Chief Medical Officer Craig C. Hopkinson Disposes of 9,000 Shares for $422,874","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","PSCH","ALKS","FBT","BK4139","PSIL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855897","title":"Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855897","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855897?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:00","pubTimestamp":1788260400,"startTime":"0","endTime":"0","summary":"– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3353967/0/en/upstream-bio-announces-pivotal-phase-3-development-plans-for-verekitug-in-both-severe-asthma-and-crswnp.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07366","TLA","09766","TSLG","TSLI","CRSH","TESL","TSII","TSDD","TSL","TSLR","TSLY","TSLQ","TSLZ","TSLP","TSLL","07766","TSLT","TSLW","BBC","TSYY","TSLS","PSIL","TESC","TEST","09366","LABU","TSLO","ELOL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}